We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00561340
Recruitment Status : Completed
First Posted : November 20, 2007
Results First Posted : February 9, 2015
Last Update Posted : February 9, 2015
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to see if supplementing calories with Pediasure is effective in maintaining height, weight, and BMI percentiles for young children during 2 years of treatment with ADHD medication.

Condition or disease Intervention/treatment Phase
ADHD Dietary Supplement: Pediasure Behavioral: Nutritional counseling Phase 4

Detailed Description:

This is a pilot study evaluating the effect of caloric supplementation on maintenance of growth parameters during two years of open-label atomoxetine treatment in 5 and 6 year old children with ADHD. The study will assess the efficacy of caloric supplementation in maintaining baseline percentiles for height, weight, and body mass index (BMI). Patients will be randomly assigned to receive either PediaSure for caloric supplementation, or no supplementation.

Secondary aims include assessing the tolerability and efficacy of long-term, open-label atomoxetine treatment in 5 and 6 year old children with ADHD, and obtaining adequate pilot data regarding the safety, efficacy, and potential effects of atomoxetine on growth parameters in order to submit a multisite R01 to more adequately assess atomoxetine treatment and its effects in young children with ADHD.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Caloric Supplementation During Long-Term Pharmacological Treatment of ADHD in Young Children
Study Start Date : January 2006
Primary Completion Date : September 2010
Study Completion Date : September 2010
Arms and Interventions

Arm Intervention/treatment
Experimental: 1 Can of Pediasure Supplement Plus Nutritional Counseling
Pediasure and nutritional counseling
Dietary Supplement: Pediasure
50% will be randomized to pediasure with nutritional counseling
Behavioral: Nutritional counseling
50% randomized to nutritional counseling only
Active Comparator: Counseling by the Provider on Ways to Encourage Caloric Intake
Behavioral intervention - Nutritional Counseling
Behavioral: Nutritional counseling
50% randomized to nutritional counseling only

Outcome Measures

Primary Outcome Measures :
  1. Weight Change [ Time Frame: 6 months ]
    Change in weight observed from baseline to 6 months

  2. Height Change [ Time Frame: 6 months ]
    Change in height from baseline to 6 months

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 9 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children who participated in the 8 week DBPC trial of atomoxetine (1K23MH066127) who wish to participate in a long-term, open label trial of atomoxetine.
  • Parents and patients must be able to attend regular study visits. Visits will be scheduled every 30 days for the first 6 months and then every 60 days for the next 18 months.
  • Children who are on alternate medications due to inefficacy or intolerability of atomoxetine may still participate.

Exclusion Criteria:

  • Parents who are unwilling to provide informed consent.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00561340

United States, Nebraska
University of Nebraska Medical Center, Department of Psychiatry
Omaha, Nebraska, United States, 68105
Sponsors and Collaborators
University of Nebraska
Principal Investigator: Christopher J Kratochvil, MD University of Nebraska
More Information

Responsible Party: Christopher J. Kratochvil, M.D., Professor, Psychiatry and Pediatrics, University of Nebraska
ClinicalTrials.gov Identifier: NCT00561340     History of Changes
Other Study ID Numbers: 356-05-FB
B4Z-US-X018 ( Other Identifier: Eli Lilly and Company )
11112 ( Other Identifier: Abbott Laboratories )
First Posted: November 20, 2007    Key Record Dates
Results First Posted: February 9, 2015
Last Update Posted: February 9, 2015
Last Verified: January 2015

Keywords provided by Christopher J. Kratochvil, M.D., University of Nebraska: